Clinical trial · Interventional
19F Thoracic Radiotherapy for Lung Cancer
Feasibility Study to Determine Utility of 19F MRI for Regional Pulmonary Function Assessment in Patients Receiving Thoracic Radiotherapy for Lung Cancer
NCT03315065CI-TRIAL-00039504completedEarly Phase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this study is to determine the feasibility and efficiency of incorporating 19F MR functional lung imaging into the routine assessment of lung cancer patients prior to thoracic radiotherapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Perfluorinated Gas/Oxygen Mixture | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Patients diagnosed with Lung cancer
- description
- patients diagnosed with Lung cancer and Thoracic radiotherapy
- interventionNames
- Drug: Perfluorinated Gas/Oxygen Mixture
Primary outcomes (2)
- measure
- Number of study patients consented (maximum 8)in order to result in 5 patients successfully completing both 19F functional MR imaging data sets
- timeFrame
- 4 months
- measure
- Proportion of study patients that successfully return for a re-assessment 19F MRI scan after completing radiotherapy.
- timeFrame
- 6 weeks after completing RT
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 99 Years
Show eligibility criteria text
Inclusion Criteria: * Subject has histologic or cytologic confirmation of lung cancer (NSCLC or Small cell) and has been recommended thoracic radiotherapy as part of standard of care management. * Ability to undergo MR imaging, tolerate breath hold procedures and follow direction during the imaging process * Karnofsky performance status ≥60, with expected survival of ≥6 months * At least 18 years of age * Patient is not pregnant * Patient can be reliably reached for post-MRI follow up AE check. * Patient able to sign a study specific informed consent form. Exclusion Criteria: * Any condition including, metallic implants or cardiac pacemakers that makes the candidate ineligible for MR imaging. (MRI research screening form will be completed prior to each MRI scan). * Malignant pleural effusion or pericardial effusion
References
Publications (0)
Data not yet available
No reference posted for this study.